KDR and breast carcinoma: The data in clinical study (NCT01639911) demonstrate that MLN8237 and the tyrosine kinase inhibitors of vascular endothelial growth factor receptor (VEGFR) can partially alleviate the symptom of patients with breast cancer (34).